# Astrana Health Inc. (ASTH) Stock Analysis: 46% Potential Upside Beckons Investors

- Link: https://www.directorstalkinterviews.com/astrana-health-inc-asth-stock-analysis-46-potential-upside-beckons-investors/4121245055
- Published: 2026-03-17T11:25:52+00:00
- Author: Madison Wilson

Astrana Health Inc. (NASDAQ: ASTH) is emerging as a notable player in the healthcare
sector, particularly within the medical care facilities industry. With a market 
capitalization of $1.37 billion, Astrana Health is positioning itself as a promising
investment opportunity, offering diversified medical care services across the United
States. The company, formerly known as Apollo Medical Holdings, Inc., underwent 
a rebranding in February 2024, reflecting its evolving strategy and growth ambitions.

One of the most compelling aspects of Astrana Health’s current financial standing
is the significant potential upside of 46.34% based on the average target price 
set by analysts. Currently trading at $24.60, the stock’s price is well within its
52-week range of $18.16 to $34.05, providing a lucrative entry point for investors
eyeing long-term gains.

Astrana Health’s valuation metrics present a mixed picture. While the trailing P/
E ratio is not available, the forward P/E ratio stands at a compelling 8.23, indicating
that the stock might be undervalued relative to its earnings potential. The absence
of a PEG ratio and other valuation metrics like Price/Book and Price/Sales suggests
that investors should exercise caution and consider other performance indicators
when evaluating the stock.

The company’s performance metrics reveal robust revenue growth of 42.90%, underscoring
its aggressive expansion and operational effectiveness. With an EPS of $0.46 and
a return on equity of 4.49%, Astrana Health demonstrates its ability to generate
profit and return value to shareholders, albeit with room for improvement in profitability
metrics. Moreover, the company boasts a substantial free cash flow of approximately
$227.9 million, providing it with the financial flexibility to invest in growth 
initiatives and weather economic downturns.

Despite the absence of a dividend yield, Astrana Health’s zero payout ratio highlights
its reinvestment strategy, focused on fueling future growth rather than distributing
profits as dividends. This approach aligns with the company’s expansive revenue 
growth and suggests a reinvestment in its core operations and strategic initiatives.

Analyst sentiment towards Astrana Health is overwhelmingly positive, with nine buy
ratings and just two hold ratings, suggesting strong confidence in the company’s
growth trajectory. The target price range of $26.00 to $50.00 further supports the
notion of significant upside potential, with an average target price of $36.00.

From a technical perspective, Astrana Health’s stock hovers near its 50-day moving
average of $23.53 but remains below its 200-day moving average of $25.82, indicating
a potential reversal if the stock gains momentum. The Relative Strength Index (RSI)
of 46.91 suggests the stock is neither overbought nor oversold, providing a neutral
ground for technical traders. Meanwhile, the MACD of 0.66, above the signal line
of 0.44, hints at a bullish trend that could attract momentum investors.

Astrana Health Inc., with its comprehensive offerings across care coordination, 
delivery, and enablement, serves a broad patient base, including those covered by
Medicare, Medicaid, and other health plans. This diversified patient base, combined
with robust growth metrics, positions Astrana Health as a formidable contender in
the healthcare sector, appealing to investors looking for growth-oriented stocks
with substantial upside potential. As the company continues to leverage its expansive
network of healthcare professionals and facilities, investors will be keenly watching
its performance and strategic moves in the coming quarters.

Share on:
